Parkinson’s disease (PD) is a progressive neurodegenerative disorder. However, cell type–dependent transcriptional regulatory programs responsible for PD pathogenesis remain elusive. Here, we establish transcriptomic and epigenomic landscapes of the substantia nigra by profiling 113,207 nuclei obtained from healthy controls and patients with PD. Our multiomics data integration provides cell type annotation of 128,724 cis-regulatory elements (cREs) and uncovers cell type–specific dysregulations in cREs with a strong transcriptional influence on genes implicated in PD. The establishment of high-resolution three-dimensional chromatin contact maps identifies 656 target genes of dysregulated cREs and genetic risk loci, uncovering both potential and known PD risk genes. Notably, these candidate genes exhibit modular gene expression patterns with unique molecular signatures in distinct cell types, highlighting altered molecular mechanisms in dopaminergic neurons and glial cells including oligodendrocytes and microglia. Together, our single-cell transcriptome and epigenome reveal cell type–specific disruption in transcriptional regulations related to PD.
Brain organoids are an exciting new technology with the potential to significantly change our understanding of the development and disorders of the human brain. With step-by-step differentiation protocols, three-dimensional neural tissues are self-organized from pluripotent stem cells, and recapitulate the major millstones of human brain development in vitro. Recent studies have shown that brain organoids can mimic the spatiotemporal dynamicity of neurogenesis, the formation of regional neural circuitry, and the integration of glial cells into a neural network. This suggests that brain organoids could serve as a representative model system to study the human brain. In this review, we will overview the development of brain organoid technology, its current progress and applications, and future prospects of this technology.
The transition of endothelial cells (EC) to tumor-associated ECs (TEC) is a critical process in tumor progression. The underlying mechanisms driving this angiogenic state could represent potential therapeutic targets. In this study, we revealed that a co-opted gene regulatory program from EC progenitors promotes the angiogenic phenotypes of TECs. Specifically, the TEC-specific gene regulatory program, derived from large-scale single-cell transcriptomic and epigenomic atlases across multiple solid tumors, was projected onto multiomic maps of human embryonic stem cell–derived EC differentiation. TECs reactivated a gene regulatory program governing extracellular matrix remodeling originally confined to the late EC progenitor state. Notably, integrin αv emerged as a mediator associated with endothelial plasticity in the tumor microenvironment (TME). Stimulation of primary ECs with predicted TME ligands reactivated these progenitor-associated regulatory programs, whereas inhibition of integrin αv attenuated this effect, suppressing endothelial migration, invasion, and tumor vascularization in vivo. Collectively, these findings reveal that tumor endothelial plasticity is governed by the co-option of a developmental cis-regulatory program, highlighting a regulatory mechanism underlying TEC adaptation in tumors and providing a rational therapeutic strategy to counteract angiogenic reprogramming. Significance: Tumors exploit intrinsic endothelial differentiation programs to drive vascular evolution, providing a conceptual framework for targeting endothelial plasticity as an anti-angiogenic strategy.